All News

RheumNow Podcast square

How Often Do You Monitor MTX? (6.16.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening. 

Read Article
depression oh no HA

Why Depression Screening Should be Mandatory at Each Visit

Jack Cush, MD

Depression is more widespread than ever in the United States, according to a new study from Gallup, showing that 18% of adults are depressed (or receiving depression treatment for depression) – an increase in 7 percentage points since 2015. 

Read Article
RA.Ow02.jpg

High Mortality Rates with Depression in Rheumatoid Arthritis

Jack Cush, MD

A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA).  

Read Article
biosim.sign_.jpg

Biosimilars Match Biologic Originators in Rheumatoid Arthritis

Jack Cush, MD

A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).

Read Article
RheumNow Podcast square

EULAR 2023 Notes from Milan (6.09.2023)

Jack Cush, MD

Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.

Read Article
question-mark-1872634_640.jpg

Combining a Tyk2 inhibitor with a JAKi in RA?

Janet Pope, MD, MPH, FRCPC

At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.

Read Article
Hands holding shingles sign

Zoster protection for JAK inhibitor patients appears achievable

David Liew, FRACP

One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.

Read Article
Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/fA6gzta5rx https://t.co/mGdzTqjEr7

Links:

Dr. John Cush RheumNow ( View Tweet)
High Mortality Rates with Depression in Rheumatoid Arthritis A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA). https://t.co/R2MB4bs0Hr https://t.co/rWIfHmBqr8

Links:

Dr. John Cush RheumNow ( View Tweet)
TNR- Rheumatoid Arthritis - Decisive Therapeutics Replay of this RA pod from RheumNow Live 2023, recorded on March 18, 2023 https://t.co/RyyKQFDrT5 https://t.co/ZHjJRzHJ0Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Karolinska SARA (secretory antibodies in RA) study of 132 RA pts found salivary IgA anti-RgpB Abs signif higher in RA than (p = 0.022), & were assoc w/ disease activity (p = 0.036), but not with periodontitis or serum IgG ACPA. https://t.co/4uul4b5Fhg https://t.co/R5WVCyjc3B

Links:

Dr. John Cush RheumNow ( View Tweet)
Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/6OVZhkTdGc https://t.co/3VHhI7nfQm

Links:

Dr. John Cush RheumNow ( View Tweet)
Assessing CV Risk in Inflammatory Arthritis: Which Score? Dr. Aurelie Najm discusses OP0267 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/qlJ9iMwrip @AurelieRheumo https://t.co/Yh2siy6555

Links:

Dr. John Cush RheumNow ( View Tweet)
Postpartum Depression in RA Dr. Jonathan Kay discusses abstract POS0206-HPR at EULAR 2023 in Milan, Italy. https://t.co/dzUMIia8Q6 https://t.co/IjeEvz8Cab

Links:

Dr. John Cush RheumNow ( View Tweet)
JAKi in Rheumatoid Arthritis: Cancer and Cardiovascular Risks Dr. Antoni Chan discusses abstracts OP0132, POS0831, and OP0133 presented at EULAR 2023 in Milan, Italy. https://t.co/ApLaPf7uKP https://t.co/nbZgwIlHyb

Links:

Dr. John Cush RheumNow ( View Tweet)
Abatacept: is there a role before RA hits? Dr. David Liew discusses OP0130 at EULAR 2023 in Milan, Italy. https://t.co/XJXabAULhn https://t.co/Hv93HKolKH

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Zoster Management and Vaccination Drs. Janet Pope and Kevin Winthrop at EULAR 2023 in Milan, Italy. https://t.co/eOhXzw3Epy https://t.co/h3NoDggg5x

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate - an old trusted friend who deserves better MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice. https://t.co/rSHsysJQ46 https://t.co/OKfBiMlqyg

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Arthritis, Radiomics and Interstitial Lung Disease Drs. Antoni Chan and Vincenzo Venerito discuss abstracts OP0127 and POS0855 presented at EULAR 2023 in Milan, Italy. https://t.co/SuMMrkwfvk https://t.co/hSSPKIW4Os

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult to treat RA is Actually Difficult to Define Dr. Janet Pope discusses abstract OP0134 presented at EULAR 2023 in Milan, Italy. https://t.co/0J9mH9n8jJ https://t.co/JT1hGp2S5w

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×